Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized salbutamol via high-flow nasal oxygen in acute COPD decompensation
2017-001579-22Phase 3Completed
- Sponsor
- CHU de Poitiers
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of salbutamol in chronic obstructive pulmonary disease (COPD), sponsored by CHU de Poitiers. Primary endpoint: Change in FEV1 over time. Started Jun 2017; status: completed.
02
Drugs
salbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-001579-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001579-22.